CELSR1 enhances doxorubicin resistance by activating the WNT/PCP signaling pathway in breast cancer cells

Doxorubicin (Dox) is a widely used chemotherapy drug to inhibit the growth and survival of human breast cancer (BC) cells. Presently, there is a pressing need for the development of new therapeutic strategies to enhance Dox efficacy by overcoming the resistance exhibited by breast cancer cells. Cadherin EGF LAG seven-pass G-type receptor 1 (CELSR1), belonging to the Flamingo subfamily, has been implicated in the progression of various tumors. However, the specific role and mechanisms of CELSR1 in the resistance of breast cancer to drug treatments have yet to be fully understood. This study aims to clarify the role of CELSR1 in conferring resistance to doxorubicin in breast cancer. Our findings demonstrate that CELSR1 expression is elevated in breast cancer tissues. Silencing of CELSR1 significantly reduced the proliferation and motility of breast cancer cells. Moreover, the ablation of CELSR1 decreased the resistance of breast cancer cells to doxorubicin treatment. At the molecular level, CELSR1 was found to activate the Wnt/Planar Cell Polarity (WNT/PCP) signaling pathway in breast cancer cells. In conclusion, CELSR1 plays a crucial role in promoting the migration of breast cancer cells and in enhancing their resistance to doxorubicin through the activation of the WNT/PCP pathway.

Breast cancer (BC); Cancer multidrug resistance; Doxorubicin (Dox); CELSR1; WNT/PCP pathway

[1] Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993–2015: population based observational cohort study. The BMJ. 2023; 382: p1744.

[2] Ghezelayagh TS, Wu ES, Barber EL, Dao MD, Zsiros E, Urban RR, et al. Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study. European Journal of Gynaecological Oncology. 2023; 44: 17–25.

[3] Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annual Review of Pathology: Mechanisms of Disease. 2022; 17: 181–204.

[4] Haffez H, Osman S, Ebrahim HY, Hassan ZA. Growth inhibition and apoptotic effect of pine extract and abietic acid on MCF-7 breast cancer cells via alteration of multiple gene expressions using in vitro approach. Molecules. 2022; 27: 293.

[5] Wohlfromm F, Seyrek K, Ivanisenko N, Troitskaya O, Kulms D, Richter V, et al. RL2 enhances the elimination of breast cancer cells by doxorubicin. Cells. 2023; 12: 2779.

[6] Mody H, Vaidya TR, Lezeau J, Taha K, Ait-Oudhia S. In vitro to clinical translation of combinatorial effects of doxorubicin and dexrazoxane in breast cancer: a mechanism-based pharmacokinetic/pharmacodynamic modeling approach. Frontiers in Pharmacology. 2023; 14: 1239141.

[7] Maltese PE, Michelini S, Ricci M, Maitz S, Fiorentino A, Serrani R, et al. Increasing evidence of hereditary lymphedema caused by CELSR1 loss-of-function variants. American Journal of Medical Genetics Part A. 2019; 179: 1718–1724.

[8] Basta LP, Sil P, Jones RA, Little KA, Hayward-Lara G, Devenport D. Celsr1 and Celsr2 exhibit distinct adhesive interactions and contributions to planar cell polarity. Frontiers in Cell and Developmental Biology. 2022; 10: 1064907.

[9] Wei S, Qi L, Wang L. Overexpression of circ_CELSR1 facilitates paclitaxel resistance of ovarian cancer by regulating miR-149-5p/SIK2 axis. Anti-Cancer Drugs. 2021; 32: 496–507.

[10] Alpaslan M, Mestre-Godin S, Lay A, Giacalone G, Helaers R, Adham S, et al. Ureteropelvic junction obstruction with primary lymphoedema associated with CELSR1 variants. Journal of Medical Genetics. 2023; 60: 1161–1168.

[11] Wang G, Li Y, Zhang D, Zhao S, Zhang Q, Luo C, et al. CELSR1 acts as an oncogene regulated by miR-199a-5p in glioma. Cancer Management and Research. 2020; 12: 8857–8865.

[12] Hummel D, Becks A, Men H, Bryda EC, Glasco DM, Chandrasekhar A. Celsr1 suppresses Wnt5a-mediated chemoattraction to prevent incorrect rostral migration of facial branchiomotor neurons. Development. 2022; 149: dev200553.

[13] Bui DLH, Roach A, Li J, Bandekar SJ, Orput E, Raghavan R, et al. The adhesion GPCRs CELSR1–3 and LPHN3 engage G proteins via distinct activation mechanisms. Cell Reports. 2023; 42: 112552.

[14] Zuo J, Zheng A, Wang X, Luo Z, Chen Y, Cheng X, et al. Upregulation of CELSR1 expression promotes ovarian cancer cell proliferation, migration, and invasion. Medical Oncology. 2023; 41: 10.

[15] Stahley SN, Basta LP, Sharan R, Devenport D. Celsr1 adhesive interactions mediate the asymmetric organization of planar polarity complexes. eLife. 2021; 10: e62097.

[16] Usami FM, Arata M, Shi D, Oka S, Higuchi Y, Tissir F, et al. Intercellular and intracellular cilia orientation is coordinated by CELSR1 and CAMSAP3 in oviduct multi-ciliated cells. Journal of Cell Science. 2021; 134: jcs257006.

[17] Rogers S, Zhang C, Anagnostidis V, Liddle C, Fishel ML, Gielen F, et al. Cancer-associated fibroblasts influence Wnt/PCP signaling in gastric cancer cells by cytoneme-based dissemination of ROR2. Proceedings of the National Academy of Sciences. 2023; 120: e2217612120.

[18] Luga V, Zhang L, Viloria-Petit A, Ogunjimi A, Inanlou M, Chiu E, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012; 151: 1542–1556.

[19] Hu Y, Liu J, Lu J, Wang P, Chen J, Guo Y, et al. SFRP1 protects H9c2 cardiac myoblasts from doxorubicin-induced apoptosis by inhibiting the Wnt/PCP-JNK pathway. Acta Pharmacologica Sinica. 2020; 41: 1150–1157.